FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 13587.286	APPLICATION NO. 09/523,102
	APPLICANTS SI, *et al.*	
	FILING DATE March 10, 2000	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes	TRANSLATION No
	AE1	EP 0312208	09/1988	EP				
	AF1	WO 9529696 A1	11/1995	WO				
	AG1	WO 9603985 A1	02/1996	WO				
	AH1	WO 9741844 A1	11/1997	WO				
	AI1	WO 9810758 A1	03/1998	WO				
	AJ1	WO 9913909 A1	03/1999	WO				
	AK1	WO 9945929 A1	09/1999	WO				
	AL1	WO 0007565 A2	02/2000	WO				
	AM1	WO 0007565 A3	02/2000	WO				
	AN1	EP 1040837 A2	10/2000	EP				
	AO1							
	AP1							

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AQ1		Baraldi, *et al.*, *Synthesis, in Vitro Antiproliferative Activity, and DNA-Binding Properties of Hybrid Molecules Containing Pyrrola* [2.1-c][1.4]b benzodiazepine and Minor-Groove-Binding Oligopyrrole Carriers, Journal of Medical Chemistry 42(25): 5131-41 (1999).
	AR1		Bayless, *et al.*, *RGD-Dependent Vacuolation and Lumen Formation Observed during Endothelial Cell Morphogenesis in Three-Dimensional Fibrin Matrices Involves the a_vB_3 and a_5B_1 Integrins,* American Journal of Pathology 156(5): 1673-83 (2000).
	AS1		Bevilacqua, *et al.*, *Recent Contributions to Knowledge of the Mechanism of Action of Nimesulide*, Drugs 46 Suppl. 1: 40-47 (1993).
	AT1		Bigg, *et al.*, *Mechanisms of induction of human tissue inhibitor of metalloproteinases-1 (TIMP-1) gene expression by all-trans retinoic acid in combination with basic fibroblast growth factor*, European Journal of Biochemistry 267(13): 4150-56 (2000).
	AU1		Binetruy-Tournaire, *et al.*, *Identification of a peptide blocking vascular endothelial growth factor (VEGF)-mediated angiogenesis*, EMBO J. 19(7): 1525-33 (2000).
	AV1		Campbell, *et al.*, *Malonyl aa-Mercaptoketones and a-Mercaptoalcohols, A New Class of Matrix Metalloproteinase Inhibitors*, Bioorganic Medical Chemistry Letters 8(10): 1157-62 (1998).

EXAMINER	DATE CONSIDERED
	2/25/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449
INFORMATION DISCLOSURE STATEMENT

ATTY. DOCKET NO.	APPLICATION NO.
13587.286	09/523,102
APPLICANTS	
SI, *et al.*	
FILING DATE	GROUP
March 10, 2000	

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AW2						
	AX2						
	AY2						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes	TRANSLATION No
	AZ2							
	BA2							
	BB2							

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

S	BC2		Cherney, *et al.*, *Macrocyclic Hydrozamate Inhibitors of Matrix Metalloproteinases and TNF-a Production,* Bioorganic Medical Chemistry Letters 9(9): 1279-84 (1999).
S	BD2		Colombo, S., *et al.*, "An Eye Drop Form of an Extracellular Proteinase Inhibitor Prevents Retinal Neovascularization in an Animal Model," Biosciences Information Service cited as XP002183948 on the International Search Report dated March 15, 2000.
S	BE2		Colorado, *et al.*, Anti-angiogenic Cures From Vascular Basement Membrane Collagen, Cancer Research 69(9): 2520-26 (2000).
S	BF2		Coors, *et al.*, The Investigative Ophthalmology & Visual Sciences 40(4): S231 (1999).
S	BG2		Dark, *et al.*, *Combretastatin A-4, an Agent that Displays Potent and Selective Toxicity toward Tumor Vasculature*, Cancer Research 57 (10): 1829-34 (1997).
S	BH2		Fairbrother, *et al.*, *Novel Peptides Selected to Bind Vascular Endothelial Growth Factor Target the Receptor-Binding Site*, Biochemistry 37(51): 17754-64 (1998).
S	BI2		Fife, *et al.*, Effects of tetracyclines on angiogenesis in vitro, Cancer Letters. 153(1-2): 75-8 (2000).
S	BJ2		Fini, *et al.*, *An Inhibitor of the Matrix Metalloproteinase Synthesized,* Invest. Ophthalmol. Vis. Sci. 32(11): 2997-3001 (1991).
S	BK2		Floege, *et al.*, *Novel Approach to Specific Growth Factor Inhibition in Vivo*, American Journal of Pathology 154(1): 169-79 (1999).
S	BL2		Gilbertson-Beadling, *et al.*, *The tetracycline analogs minocycline and doxycycline inhibit angiogenesis in vitro by a non-metalloproteinase-dependent mechanism, Cancer Chemother, Pharmacol. 36(5): 418-24 (1995).*
S	BM2		Greenwald, *et al.*, *Tetracyclines Suppress Matrix Metalloproteinase Activity in Adjuvant Arthritis and in Combination with Flurbiprofen, Ameliorate Bone Damage,* Journal of Rheumatology 19(6): 927-38 (1992).
S	BN2		Griscelli, *et al.*, *Angiostatin gene transfer: Inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest,* Proceedings of the National Academy of Sciences U.S.A., 95(11): 6367-72 (1998).
S	BO2		Hanessian, *et al.*, *Picking The S_1, S_1 and S_2 Pockets of Matrix Metalloproteinases, A Niche for Potent Acyclic Sulfonamide Inhibitors,* Bioorganic Medical Chemistry Letters 9(12): 1691-96 (1999).
S	BP2		Hanglow, *et al.*, *Peptides based on the conserved prodomain sequence of matrix metalloproteinases inhibit human stromelysin and collagenase, Agents Actions 39 Spec. No.: C148-50 (1993).*

EXAMINER	DATE CONSIDERED
	9/25/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 13587.286	APPLICATION NO. 09/523,102
	APPLICANTS SI, *et al.*	
	FILING DATE March 10, 2000	GROUP

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	BQ3						
	BR3						
	BS3						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes	TRANSLATION No
	BT3							
	BU3							
	BV3							

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	BW3		~~International Search Report, Application No. PCT/US01/07171, filed March 7, 2001.~~
	BX3		Investigative Opthalmology Visual Science, Vol. 41, No. 4, S640 (2000).
	BY3		Jacobson, *et al., Structure-Based Design and Synthesis of a Series of Hydroxamic Acids With a Quaternary-Hydroxy Group in P1 As Inhibitors of Matrix Metalloproteinases, Bioorganic Medical Chemistry Letters 8(7): 837-42 (1998).*
	BZ3		Kawakami, *et al.,* XP 002201344 – AN 1999 – 2290406 *"Corneal neovascularization inhibitor useful e.g. with corneal grafts,"* Abstract WO 9913909 (1999).
	CA3		Kishnani, *et al., Identification and Characterization of Human Tissue Inhibitor of Metalloproteinase-3 and Detection of Three Additional Metalloproteinse Inhibitor Activities in Extracellular Matrix,* Matrix Biology 14(6): 479-88 (1995).
	CB3		Klement, *et al., Continuous low-dose therapy with vinblastine and VEGF receptor-2 antiboyd induces sustained tumor regression without overt toxicity,* J. Clin. Invest. 105(8): R15-24 (2000).
	CC3		Klein, *et al., The Wisconsin Epidemiologic Study of Diabetic Retinopathy,* Arch. Ophth. 112: 1217-1228 (1994).
	CD3		Lyons-Giordano, *et al., The Effect of Heparin on Fibronectin and Thrombospondin Synthesis and mRNA Levels in Cultured Human Endothelial Cells,* Exp. Cell Research 186(1): 39-46 (1990).
	CE3		Melchiori, *et al., Inhibition of Tumor Cell Invasion of a Highly Conserved Peptide Sequence from the Matrix Metalloproteinase Enzyme Prosegment,* Cancer Research 52(8): 2353-56 (1992).
	CF3		Murphy, A.N., *et al., Tissue Inhibitor of Metalloproteinases-2 Inhibits bFGF-Induced Human Microvascular Endothelial Cell Proliferation,* Journal of Cell Physiology 157(2): 351-58 (1993).
	CG3		Murphy, G., *et al., The N-Terminal Domain of Tissue Inhbitor of Metalloproteinases Retains Metalloproteinase Inhibitory Activity,* Biochemistry 30(33): 8097-102 (1991).
	CH3		Odake, *et al., Inhibition of Matrix Metalloproteinases By Peptidyl Hydroxamic Acids,* Biochem Biophys Res Commun 199(3): 1442-46 (1994).
	CI3		Ostendorf, *et al., VEGF $_{165}$ mediates glomerular endothelial repair,*

EXAMINER	DATE CONSIDERED
	2/25/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT	ATTY. DOCKET NO. 13587.286	APPLICATION NO. 09/523,102
	APPLICANTS SI, *et al.*	
	FILING DATE March 10, 2000	GROUP TECH CENTER 1600/2900

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	CJ4						
	CK4						
	CL4						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION Yes	No
	CM4							
	CN4							
	CO4							

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	CP4		Pikul, *et al.*, *Design and Synthesis of Phosphinamide-Based Hydroxamic Acids as Inhibitors of Matrix Metalloproteinases,* Journal of Medical Chemistry 42(1): 87-94 (1999).
	CQ4		Possati, *et al.*, Antiangiogenic, antitumoural and antimetastatic effects of two distamycin A derivatives with anti-HIV-1 Tat activity in Kaposi's sarcoma-like murine model, Clin. Exp. Metastatis 17(7): 575-82 (1999).
	CR4		Shapiro, *et al.*, *Dexamethasone Selectively Modulates Basal and Lipopolysaccharide-Induced Metalloproteinase and Tissue Inhibitor of Metalloproteinase Production By Human Alveolar Macrophages*, Journal of Immunology 146(8): 2724-29.
	CS4		Siemeister, *et al.*, An antagonistic vascular endothelial growth factor (VEGF): variant inhibits VEGF-stimulated receptor autophosphorylation and proliferation of human endothelial cells, Proceedings of the National Academy of Sciences U.S.A. 95: 4625-29 (1998).
	CT4		Stack, *et al.*, *Application of N-Carboxyallkyl Peptides to the Inhibition and Affinity Purification of the Porcine Matrix Mettoproteniases Collagenase, Gelatinase, and Stromelysin,* Arch. Biochem. Biophys. 287(2): 240-49 (1991).
	CU4		Steinman, *et al.*, *The Design, Synthesis, and Structure-Activity Relationships of a Series of Macrocyclic MMP Inhibitors,* Bioorganic Medical Chemistry Letters 8(16): 21087-92 (1998).
	CV4		Sunamura, *et al.*, *The Antiangiogenesis Effect of Interleukin 12 During Early Growth of Human Pancreatic Cancer in SCID Mice. Pancreas 20(3): 227-33 (2000).*
	CW4		Wallon, *et al.*, *Polyamine-Dependent Expression of the Matrix Mettaloproteinase Matrilysin in a Human Colon Cancer-Derived Cell Line, Mol. Carcinog, 11(3): 138-44 (1994).*
	CX4		Wentworth, *et al.*, Effect of a Metalloproteinase Inhibitor on Established Corneal Ulcers After an Alkali Burn, Invest. Ophthalmol. Vis. Sci. 33(7): 2174-79 (1992).
	CY4		Willis, *et al.*, *Liposome-Anchored Vascular Endothelial Growth Factor Aptamers,* Bioconjug. Chem. 9(5): 573-82 (1998).
	CZ4		Zhang, *et al.*, *Structural interaction of natural and synthetic inhibitors with the venom metalloproteinase, atrolysin C (form d)*, Proceedings of the National Academy of Sciences U.S.A. 91: 8447-51 (1994).
	DA4		
	DB4		

EXAMINER	DATE CONSIDERED 2/25/03

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.